Snezhina Lazova

Dr. Snezhina Lazova

UMHATEM "N.I.Pirogov", Pediatric department (Sofia, Bulgaria)
+1
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2023 in World Journal of Transplantation
Verified
Journal Article
Open access
PKPlamena Kabakchieva
Plamena Kabakchieva
YAYavor Assyov
Yavor Assyov
Stavros GerasoudisStavros Gerasoudis
Stavros Gerasoudis
GVGeorgi Vasilev Vasilev
Georgi Vasilev Vasilev
Monika Peshevska-SekulovskaMonika Peshevska-Sekulovska
Monika Peshevska-Sekulovska
Tsvetelina VelikovaTsvetelina Velikova
Tsvetelina Velikova
Islet transplantation-immunological challenges and current perspectives

15 September 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
Snezhina LazovaSnezhina Lazova
Snezhina Lazova
TATea Alexandrova
Tea Alexandrova
NGNadzhie Gorelyova-Stefanova
Nadzhie Gorelyova-Stefanova
KAKalin Atanasov
Kalin Atanasov
ITIren Stoyanova Tzotcheva
Iren Stoyanova Tzotcheva
Tsvetelina VelikovaTsvetelina Velikova
Tsvetelina Velikova
SARS-CoV-2 infection may precede and cause various autoimmune and inflammatory diseases, including multisystem inflammatory syndrome in children (MIS-C). Therefore, we aimed to observe the clinical presentation and laboratory, instrumental and other constellations in children with MIS-C, including liver involvement. We present the outcomes from a single-center prospective observational study in which 89 children was included (60 with proven COVID-19, 10 symptomatic with confirmed COVID-19 contact and 19 diagnosed with MIS-C). Laboratory, instrumental, immunological, and clinical investigations were performed. Only 12% (n = 4) from the COVID-19 group (except the ICU cases), we found elevated AST and/or ALT (up to 100). All of the children with elevated transaminase were overweight or obese, presenting along with moderate COVID-19 pneumonia. The majority of children with MIS-C showed typical laboratory constellations with higher levels of IL-6 (120.36 ± 35.56 ng/mL). About half of the children in the MIS-C group (52%, n = 11) showed elevated transaminases. Eleven children (57.9%) presented with abdominal pain, eight (42.1%) with ascites, two (10.5%) with hepatosplenomegaly, and four (21.1%) with symptoms such as diarrhea. Mesenteric lymphadenitis was observed more often in patients with elevated LDH (327.83 ± 159.39, p = 0.077). Ascites was associated with lymphopenia (0.86 ± 0.80, p = 0.029) and elevated LDH. Hepato-splenomegaly was also more frequent in children with lymphopenia (0.5 ± 0.14, p = 0.039), higher troponin (402.00 ± 101.23, p = 0.004) and low ESR. Diarrhea was more frequent in patients with lower CRP (9.00 ± 3.44 vs. 22.25 ± 2.58, p = 0.04), and higher AST and ALT (469.00 ± 349.59 vs. and 286.67 ± 174.91, respectively, p = 0.010), and D-dimer (4516.66 ± 715.83, p = 0.001). Our data suggest that the liver can also be involved in MIS-C, presenting with typical laboratory and instrumental outcomes.

26 September 2017 in Pathogens and Global Health
Verified
Journal Article
Closed access
NKNeli Korsun
Neli Korsun
SASvetla Angelova
Svetla Angelova
ITIren Tzotcheva
Iren Tzotcheva
IGIrina Georgieva
Irina Georgieva
Snezhina LazovaSnezhina Lazova
Snezhina Lazova
PPPenka Perenovska
Penka Perenovska
The respiratory syncytial virus (RSV) is a leading cause of acute respiratory illnesses (ARI) in infants and young children. The objectives of this study were to investigate the RSV circulation among children aged <5 years in Bulgaria, to identify the RSV-A and RSV-B genotypes and to perform an amino acid sequence analysis of second hypervariable region (HVR2) of the G gene. During the 2014/15 and 2015/16 winter seasons, nasopharyngeal specimens of 610 children aged <5 years with ARI were tested using Real Time RT-PCR for influenza viruses, RSV, metapneumovirus, parainfluenza viruses, rhinoviruses and adenoviruses. Viral respiratory pathogens were detected in 429 (70%) out of 610 patients examined and RSV was the most frequently identified virus (26%) followed by influenza A(H1N1)pdm09 virus (14%) (p < .05). RSV was the most prevalent pathogen in patients with bronchiolitis (48%) and pneumonia (38%). In the 2014/15 season, RSV-A dominated slightly (53%), while in the next season RSV-B viruses prevailed more strongly (66%). The phylogenetic analysis based on the G gene indicated that all 21 studied RSV-A strains belonged to the ON1 genotype; the vast majority (96%) of the RSV-B strains were classified into BA9 genotype and only one - into BA10 genotype. All Bulgarian RSV-A and RSV-B sequences contained a 72-nt and a 60-nt duplication in the HVR2, respectively. The study showed the leading role of this pathogen as a causative agent of serious respiratory illnesses in early childhood, year-on-year fluctuations in RSV incidence, a shift from RSV-A to RSV-B subgroup dominance and relatively low genetic divergence in the circulating strains.

2 August 2024 in Gastroenterology Insights
Verified
Journal Article
Open access
PDF file
Tsvetelina VelikovaTsvetelina Velikova
Tsvetelina Velikova
IKIssa El Kaouri
Issa El Kaouri
KBKonstantina Bakopoulou
Konstantina Bakopoulou
MGMilena Gulinac
Milena Gulinac
KNKremena Naydenova
Kremena Naydenova
Snezhina LazovaSnezhina Lazova
Snezhina Lazova
Mucosal immunity and trained innate immunity of the gut play a pivotal role in maintaining intestinal homeostasis and defending against microbial pathogens. This review provides an overview of the mechanisms underlying mucosal immunity and the concept of trained innate immunity in the gut. We discuss the interaction between gut microbiota and the host immune system, highlighting the role of epithelial cells, dendritic cells, and innate lymphoid cells, as well as the novel concept of trained innate immunity and its role in perpetuating or attenuating gut inflammation. We also comment on the current models for investigating mucosal immunity, their limitations, and how they can be overcome. Additionally, we explore the potential therapeutic implications of modulating mucosal immunity and trained innate immunity in gastrointestinal diseases. Only by elucidating the mechanisms underlying mucosal immunity and the concept of trained innate immunity, innovative approaches to modulate immune responses and restore intestinal homeostasis in the context of gastrointestinal disorders could be implemented.

1 April 2022 in Antibodies
Verified
Journal Article
Open access
PDF file
Snezhina LazovaSnezhina Lazova
Snezhina Lazova
YDYulia Dimitrova
Yulia Dimitrova
Diana Mitkova HristovaDiana Mitkova Hristova
Diana Mitkova Hristova
ITIren Tzotcheva
Iren Tzotcheva
Tsvetelina VelikovaTsvetelina Velikova
Tsvetelina Velikova
The newly identified strain of the Coronaviridae family called severe acute respiratory syndrome (SARS-CoV-2) recently became the most significant health threat for adults and children. Some main predictors of severe clinical course in patients with SARS-CoV-2 infection are age and concomitant health conditions. Therefore, the proper evaluation of SARS-CoV-2-specific immunity is urgently required to understand and predict the spectrum of possible clinical phenotypes and recommend vaccination options and regimens in children. Furthermore, it is critical to characterize the nature of SARS-CoV-2-specific immune responses in children following asymptomatic infection and COVID-19 and other related conditions such as multisystem inflammatory syndrome (MIS-C), para-infectious and late postinfectious consequences. Recent studies involving children revealed a variety of cytokines, T cells and antibody responses in the pathogenesis of the disease. Moreover, different clinical scenarios in children were observed-asymptomatic seroprevalence, acute SARS-CoV-2 infection, and rarely severe COVID-19 with typical cytokine storm, MIS-C, long COVID-19, etc. Therefore, to gain a better clinical view, adequate diagnostic criteria and treatment algorithms, it is essential to create a realistic picture of the immunological puzzle of SARS-CoV-2 infection in different age groups. Finally, it was demonstrated that children may exert a potent and prolonged adaptive anti-SARS-CoV-2 immune response, with significant cross-reactions against other human Corona Viruses, that might contribute to disease sparing effect in this age range. However, the immunopathology of the virus has to be elucidated first.

30 June 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
Dimitrina Georgieva MitevaDimitrina Georgieva Miteva
Dimitrina Georgieva Miteva
Meglena KitanovaMeglena Kitanova
Meglena Kitanova
HBHristiana Batselova
Hristiana Batselova
Snezhina LazovaSnezhina Lazova
Snezhina Lazova
LCLyubomir Chervenkov
Lyubomir Chervenkov
Tsvetelina VelikovaTsvetelina Velikova
Tsvetelina Velikova
Although the chief of the World Health Organization (WHO) has declared the end of the coronavirus disease 2019 (COVID-19) as a global health emergency, the disease is still a global threat. To be able to manage such pandemics in the future, it is necessary to develop proper strategies and opportunities to protect human life. The data on the SARS-CoV-2 virus must be continuously analyzed, and the possibilities of mutation and the emergence of new, more infectious variants must be anticipated, as well as the options of using different preventive and therapeutic techniques. This is because the fast development of severe acute coronavirus 2 syndrome (SARS-CoV-2) variants of concern have posed a significant problem for COVID-19 pandemic control using the presently available vaccinations. This review summarizes data on the SARS-CoV-2 variants that are responsible for severe COVID-19 and the clinical efficacy of the most commonly used vaccines in clinical practice. The consequences after the disease (long COVID or post-COVID conditions) continue to be the subject of studies and research, and affect social and economic life worldwide.